INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ:GILD). Such investors...
GILD ALERT: Levi & Korsinsky Investigates Gilead Sciences, Inc. on Behalf of Shareholders Who Lost Money
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerni...
Investigation Alert: Gilead Sciences, Inc. (GILD) Under Scrutiny - Contact Levi & Korsinsky for Details
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerni...
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
Initiate Gilead Sciences with Strong Buy/$181 PT, citing disciplined cost base, accelerating pipeline, and robust Q1-25 execution driving margin and EPS outperformance. HIV franchise resilience and...
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Daniel P. O'Day - Chairman & CEO Conference Call Participa...
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, ...
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However, we recommend investors remain on the sidelines at current levels.
Focus: Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Adm...
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
Why Gilead Sciences Stock Slipped Today
Gilead Sciences (GILD -2.85%) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its s...
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
Gilead Sciences, Inc. (GILD) Q1 2025 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier -...
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Stree...
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $1.81 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to loss of $1.32 per share a year ago.
Related Companies